
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
TKI in Poor-Risk Advanced Renal Cell Carcinoma
Case: A 68-Year-Old Man With Poor-Risk RCC
A 68-year-old man presented with a 6-week history of painless intermittent hematuria, fatigue and a 7-lb weight loss.
H & P:
Labs:
Imaging:
Diagnosis:
Treatment:
